InsiderTape plots every Form 4 on the price chart and flags cluster buys, CEO conviction, and first buys in years the moment they file. Start a free 7-day trial, cancel anytime.
START FREE TRIAL →Tobin Schilke, CFO, is a corporate insider tracked by InsiderTape across 2 companies. The public record shows 13 open-market SEC Form 4 transactions: 0 purchases worth $0 and 13 sales worth $2.3M, reported from Jan 9, 23 to Mar 3, 26. Over this period they have been a net seller.
| Date | Company | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 3, 26 | CRNXCrinetics Pharmaceuticals, Inc. | SELL | 6.7K | $39.67 | $266K |
| Mar 18, 24 | RVNCRevance Therapeutics, Inc. | SELL | 9.4K | $5.04 | $47K |
| Jul 3, 23 | RVNCRevance Therapeutics, Inc. | SELL | 1.7K | $25.04 | $43K |
| Jun 2, 23 | RVNCRevance Therapeutics, Inc. | SELL | 500 | $31.00 | $16K |
| Jun 1, 23 | RVNCRevance Therapeutics, Inc. | SELL | 2.7K | $30.57 | $83K |
| May 15, 23 | RVNCRevance Therapeutics, Inc. | SELL | 21.4K | $34.55 | $739K |
| May 1, 23 | RVNCRevance Therapeutics, Inc. | SELL | 3.2K | $31.70 | $101K |
| Apr 3, 23 | RVNCRevance Therapeutics, Inc. | SELL | 3.2K | $32.15 | $103K |
| Mar 9, 23 | RVNCRevance Therapeutics, Inc. | SELL | 18.5K | $31.59 | $585K |
| Mar 1, 23 | RVNCRevance Therapeutics, Inc. | SELL | 3.2K | $33.50 | $107K |
| Feb 1, 23 | RVNCRevance Therapeutics, Inc. | SELL | 3.2K | $34.60 | $111K |
| Jan 20, 23 | RVNCRevance Therapeutics, Inc. | SELL | 1.0K | $31.00 | $31K |
| Jan 9, 23 | RVNCRevance Therapeutics, Inc. | SELL | 1.7K | $28.00 | $43K |